Announcements Trials

Browse Landscape

Phase

Status

Completed 2 Withdrawn 1 Unknown 1 Terminated 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 4 Carcinoma, Non-Small-Cell Lung 3 Lung Neoplasms 2 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Solid Tumor 1 Skin Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Leukemia, Myelomonocytic, Chronic 1 Inflammatory Breast Neoplasms 1 Gallbladder Neoplasms 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Craniopharyngioma 1 Cholangiocarcinoma 1 Carcinosarcoma 1 Brain Neoplasms 1

Interventions

pembrolizumab 24 Carboplatin 21 Paclitaxel 20 olaparib 19 Magnetic Resonance Spectroscopy 14 Bevacizumab 14 Cyclophosphamide 12 Specimen Handling 11 Nivolumab 11 Gemcitabine 11 Taxes 10 niraparib 8 Cisplatin 8 Biopsy 8 liposomal doxorubicin 7 fludarabine 7 Surveys and Questionnaires 6 Immunoglobulin G 6 Doxorubicin 6 Disulfides 6 durvalumab 5 palbociclib 4 oregovomab 4 X-Rays 4 Ipilimumab 4 mirvetuximab soravtansine 3 ipatasertib 3 defactinib 3 cediranib 3 atezolizumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Ovarian Neoplasms × cobimetinib × Clear all

NCT04931342 2026-03-10

BOUQUET

Hoffmann-La Roche

Phase 2 Active not recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡